- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
3D Mammograms More Powerful than 2D
In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).
In the largest report to date, researchers at Washington Radiology Associates, PC, with offices in Washington, DC; Virginia; and Maryland, conducted a study of more than 59,000 patients. The results were striking: an increase in the detection rate for cancer overall of 28.6% and a 43.8% increase in detecting invasive cancers in patients screened with 3D DBT versus 2D DM.
"We observed a significant increase in the detection rate for cancer overall and an even greater increase in the detection rate for invasive cancer," said Julianne Greenberg, corresponding author of the study. "Our results may be a bellwether for the impact of tomosynthesis on population-based breast cancer screening."
American Journal of Roentgenology
The study appears ahead of print online in the .
Original report: http://bit.ly/UbH9Dx
Source: MedicalXpress
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
